

ONCE-DAILY  
**Alvesco**<sup>®</sup>  
ciclesonide

**#1 ICS MDI DISPENSED  
IN CANADA WITH  
RESPIROLOGISTS‡**




Alvesco<sup>®</sup> (ciclesonide) is indicated for prophylactic management of steroid-responsive bronchial asthma in adults, adolescents and children 6 years of age and older.

 **COVIS**  
PHARMA

### Simple Once-Daily Dosing<sup>1</sup>

- Once-daily dosing for children, adolescents and adults<sup>1</sup>
- Alvesco<sup>®</sup> is taken as 1 or 2 puffs once daily in the morning or evening.<sup>1</sup>



Age	Strength	Rx
Children 6-11	100 mcg	1-2 puffs once a day
	200 mcg	1 puff once a day
12 and up	200 mcg	2 puffs once a day

Adults and adolescents 12 years of age and older: The recommended starting dose for most patients, whether previously maintained on either bronchodilators alone or inhaled corticosteroids, is 400 micrograms once daily. The recommended dose range is 100 to 800 micrograms per day.


Alvesco<sup>®</sup> can be administered as 1 or 2 puffs once daily either in the morning or evening. Some patients with more severe asthma may be more adequately controlled on 800 micrograms daily, administered as 400 micrograms BID.

Children 6-11 years of age: The recommended starting dose for most patients, whether previously maintained on either bronchodilators alone or inhaled corticosteroids, is 100 to 200 micrograms once daily. The recommended dose range is 100 to 200 micrograms per day, administered as 1 or 2 puffs once daily either in the morning or evening.

As with all inhaled corticosteroids, the dose of Alvesco<sup>®</sup> should be adjusted according to individual response.

### Once-Daily Alvesco<sup>®</sup>: Demonstrated similar efficacy to twice-daily fluticasone propionate in patients aged 12-75 years of age<sup>1</sup>

- Improvement in FEV<sub>1</sub> with Alvesco<sup>®</sup> 100 mcg once a day was similar to fluticasone propionate 100 mcg twice daily (p<0.0001)



International, 24-week, multicentre, randomized, double-blind, double-dummy, 2-arm, parallel-group, noninferiority study. 480 patients with asthma, aged 12-75 years were randomized to Alvesco<sup>®</sup> 100 mcg OD in the evening or FP200 mcg (ex-valve, 50 mcg 2 puffs BID) for 24 weeks. The patient numbers for week 0, 2, 4, 8, 16, and 24 were n=216, 209, 198, 195, 193, and 192 (ciclesonide), and n=207, 202, 197, 194, 188, and 191 (fluticasone propionate).





### **Indications and clinical use:**

Alvesco® is indicated for the prophylactic management of steroid-responsive bronchial asthma in adults, adolescents, and children 6 years of age and older.

### **Contraindications:**

- Untreated fungal, bacterial or tuberculosis infections of the respiratory tract
- Primary treatment of status asthmaticus or other acute episodes of asthma or in patients with moderate to severe bronchiectasis

### **Relevant warnings and precautions:**

- Patients with hypothyroidism
- Patients with cirrhosis and/or severe hepatic impairment
- Immunosuppressive drugs
- May cause eosinophilic conditions
- May cause candidiasis
- As with other inhalation therapy, paradoxical bronchospasm may occur
- Caution in systemic steroid replacement by inhaled steroid
- Patients with hypoprothrombinemia in conjunction with acetylsalicylic acid
- Systemic effects of inhaled corticosteroids may occur, particularly at high doses for prolonged periods
- Monitor HPA axis function and effects on the eye

### **For more information:**

For important information on conditions of clinical use, contraindications, warnings, precautions, adverse reactions, drug interactions and dosing, please consult the product monograph at [https://pdf.hres.ca/dpd\\_pm/00060608.PDF](https://pdf.hres.ca/dpd_pm/00060608.PDF). The product monograph is available by calling Covis Pharma Canada Ltd. at 1-833-523-3009.

### **References:**

1. Alvesco® (ciclesonide) inhalation aerosol. Product Monograph, Covis Pharma GmbH, March 2021.
2. Omnaris® (ciclesonide) Product Monograph. Covis Pharma GmbH, February 2021.

† IQVIA Compuscript Data, June 2022.

Alvesco and Omnaris are registered trademarks of Covis Pharma Canada Ltd., used under licence.

© Covis Pharma Canada Ltd., 2022.





**omnaris**<sup>®</sup>  
ciclesonide

On formulary in ON and SK  
Now covered by RAMQ\*



**Omnaris**<sup>®</sup> (ciclesonide) is indicated for the treatment of seasonal allergic rhinitis, including hayfever, and perennial allergic rhinitis in adults and adolescents 12 years of age and older.


\* Official mark of the Régie de l'assurance maladie du Québec



**COVIS**  
PHARMA

### Simple Once-Daily Dosing<sup>2</sup>

- For adults and adolescents (12 years and older)



Omnaris<sup>®</sup>  
200 mcg  
per day




2 sprays  
in each nostril  
(50 mcg/spray)

- Since the effect of Omnaris<sup>®</sup> depends on its regular use, patients should be instructed to use it at regular intervals and not as they feel necessary.<sup>2</sup>

### Omnaris<sup>®</sup>: Powerful allergic rhinitis relief with an excellent tolerability profile

- Adverse events with Omnaris<sup>®</sup> were comparable to placebo in clinical trials

Common adverse reactions\* (1-10%) in a 52-week study in patients with PAR



\* Assessed as likely or definitely related to the treatment by investigator  
<sup>‡</sup> Epistaxis (e.g. frank bleeding, blood-tinged mucus and blood flecks)  
<sup>\*\*</sup> Nasal passage irritation includes nasal discomfort

### Omnaris<sup>®</sup>: Composition and storage

- Unscented - no added fragrance
- Hypotonic aqueous suspension



### **Indication:**

Omnaris® (ciclesonide) nasal spray is indicated for the treatment of seasonal allergic rhinitis, including hayfever, and perennial allergic rhinitis in adults and adolescents 12 years of age and older.

### **Contraindications:**

- Patients with tuberculosis

### **Relevant warnings and precautions:**

- Patients who are on drugs that suppress the immune system are more susceptible to infections than healthy individuals
- Patients should be examined periodically for changes or signs of adverse effects on the nasal mucosa (e.g. *Candida albicans*)
- Do not use in patients with recent nasal ulcers, nasal surgery, or nasal trauma until healing has occurred
- Monitor for growth in children and adolescents
- Use in pregnant or nursing women only if justified
- Monitor for hypoadrenalism in infants born to mothers taking corticosteroids
- Signs of adrenal insufficiency and withdrawal can accompany the replacement of a systemic corticosteroid with a topical corticosteroid; patients should be carefully monitored. Rapid decreases in systemic corticosteroid dosages following long-term treatment may cause a severe exacerbation of symptoms in patients with asthma or other clinical conditions
- Use with caution, if at all, in patients with untreated local or systemic fungal or bacterial infections, viral or parasitic infections, or ocular herpes simplex
- Use caution in patients with known hypersensitivity to other corticosteroids
- Rare instances of wheezing, nasal septum perforation, cataracts, glaucoma, increased intraocular pressure have been reported with intranasal corticosteroid use
- Not approved for use in patients younger than 12 years of age
- Greater sensitivity in some older individuals cannot be ruled out

### **For more information:**

For important information on conditions of clinical use, contraindications, warnings, precautions, adverse reactions, drug interactions and dosing, please consult the product monograph at [https://pdf.hres.ca/dpd\\_pm/00059998.PDF](https://pdf.hres.ca/dpd_pm/00059998.PDF). The product monograph is available by calling Covis Pharma Canada Ltd. at 1-833-523-3009.

### **References:**

1. Alvesco® (ciclesonide) inhalation aerosol. Product Monograph, Covis Pharma GmbH, March 2021.
2. Omnaris® (ciclesonide) Product Monograph. Covis Pharma GmbH, February 2021.

Alvesco and Omnaris are registered trademarks of Covis Pharma Canada Ltd., used under licence.

© Covis Pharma Canada Ltd., 2022.

